AR099872A1 - PROGESTERONE FORMULATIONS - Google Patents

PROGESTERONE FORMULATIONS

Info

Publication number
AR099872A1
AR099872A1 ARP150100920A ARP150100920A AR099872A1 AR 099872 A1 AR099872 A1 AR 099872A1 AR P150100920 A ARP150100920 A AR P150100920A AR P150100920 A ARP150100920 A AR P150100920A AR 099872 A1 AR099872 A1 AR 099872A1
Authority
AR
Argentina
Prior art keywords
progesterone
subject
need
amount
auc0
Prior art date
Application number
ARP150100920A
Other languages
Spanish (es)
Inventor
Persicaner Peter
Amadio Julia
Cacace Janice
Thorsteinsson Thorsteinn
Sancilio Frederick
Bernick Brian
Original Assignee
Therapeuticsmd Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therapeuticsmd Inc filed Critical Therapeuticsmd Inc
Publication of AR099872A1 publication Critical patent/AR099872A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Formulaciones de progesterona, métodos para usar estas formulaciones y sus parámetros farmacocinéticos relacionados. Las formulaciones descritas en la presente descripción permiten una reducen en la cantidad de progesterona administrada a un paciente en necesidad de esta, mientras proporciona aún los beneficios de una cantidad mayor de dosis. Reivindicación 1: Una composición farmacéutica para administrar progesterona a sujetos en necesidad de esta, la composición comprende una cantidad de progesterona y uno o más agentes solubilizantes, en donde después de la administración al sujeto en necesidad de esta, la composición produce al menos uno de los siguientes parámetros farmacocinéticos en el sujeto: a) un AUC₀₋ₜ en (ng/ml)*h de aproximadamente 5 a aproximadamente 500; b) un AUC₀₋¥ en (ng/ml)*h de aproximadamente 5 a aproximadamente 500; o c) una Cₘₐˣ en ng/ml de aproximadamente 3 a aproximadamente 350; en donde la cantidad de progesterona es menor que 200 mg. Reivindicación 10: Una composición farmacéutica para administrar progesterona a un sujeto en necesidad de esta, la composición comprende una cantidad de progesterona, uno o más agentes solubilizantes, y un surfactante no iónico seleccionado del grupo que consiste en Iauroil macrogol-32 glicéridos EP (Gelucire 44/11), Iauroil polioxil-32 gliceridos (Gelucire 44/14), y caprilocaproil macrogol-8 gicéridos EP; en donde después de la administración al sujeto en necesidad de esta, la composición produce al menos uno de los siguientes parámetros farmacocinéticos en el sujeto: a) un AUC₀₋ₜ en (ng/mI)*h de aproximadamente 5 a aproximadamente 500; b) un AUC₀₋¥ en (ng/ml)*h de aproximadamente 5 a aproximadamente 500; o c) una Cₘₐˣ en ng/ml de aproximadamente 3 a aproximadamente 350.Progesterone formulations, methods for using these formulations and their related pharmacokinetic parameters. The formulations described in the present description allow a reduction in the amount of progesterone administered to a patient in need thereof, while still providing the benefits of a larger amount of dose. Claim 1: A pharmaceutical composition for administering progesterone to subjects in need thereof, the composition comprises an amount of progesterone and one or more solubilizing agents, wherein after administration to the subject in need thereof, the composition produces at least one of the following pharmacokinetic parameters in the subject: a) an AUC₀₋ₜ in (ng / ml) * h of about 5 to about 500; b) an AUC₀₋ ¥ in (ng / ml) * h of approximately 5 to approximately 500; or c) a Cₘₐˣ in ng / ml of about 3 to about 350; where the amount of progesterone is less than 200 mg. Claim 10: A pharmaceutical composition for administering progesterone to a subject in need thereof, the composition comprises an amount of progesterone, one or more solubilizing agents, and a non-ionic surfactant selected from the group consisting of Iauroyl macrogol-32 glycerides EP (Gelucire 44/11), Iauroyl polyoxyl-32 glycerides (Gelucire 44/14), and caprilocaproyl macrogol-8 glycerides EP; wherein after administration to the subject in need thereof, the composition produces at least one of the following pharmacokinetic parameters in the subject: a) an AUC₀₋ₜ in (ng / ml) * h of about 5 to about 500; b) an AUC₀₋ ¥ in (ng / ml) * h of approximately 5 to approximately 500; or c) a Cₘₐˣ in ng / ml of about 3 to about 350.

ARP150100920A 2014-03-28 2015-03-27 PROGESTERONE FORMULATIONS AR099872A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461972068P 2014-03-28 2014-03-28

Publications (1)

Publication Number Publication Date
AR099872A1 true AR099872A1 (en) 2016-08-24

Family

ID=54196452

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150100920A AR099872A1 (en) 2014-03-28 2015-03-27 PROGESTERONE FORMULATIONS

Country Status (10)

Country Link
EP (1) EP3122364A4 (en)
JP (2) JP2017509630A (en)
KR (1) KR20160137597A (en)
AR (1) AR099872A1 (en)
AU (1) AU2015237243A1 (en)
CA (1) CA2942568A1 (en)
IL (1) IL247828A0 (en)
MX (1) MX2016011706A (en)
RU (1) RU2016136666A (en)
WO (1) WO2015148952A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020081726A1 (en) * 2018-10-17 2020-04-23 Stadler Sarah Sheehan Methods of treating menopausal symptoms using low dose progesterone
CN112336699A (en) * 2019-08-09 2021-02-09 南京科宁检测科技有限公司 Progesterone vaginal slow-release soft capsule and its preparation method
US20220105107A1 (en) * 2020-10-01 2022-04-07 Michael Liguori Bioidentical progesterone cream infused with nanoemulsified cbd

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
MXPA03000720A (en) * 2000-07-24 2004-11-01 Upjohn Co Self-emulsifying drug delivery systems for extremely water-insoluble, lipophilic drugs.
AU2002242339A1 (en) * 2002-03-14 2003-09-29 Watson Pharmaceuticals, Inc. Progesterone oral drug delivery system
AU2006249349B2 (en) * 2005-05-26 2012-01-12 Teva Women's Health, Inc. Oral dosage forms comprising progesterone and methods of making and using the same
US20110312928A1 (en) * 2010-06-18 2011-12-22 Lipocine Inc. Progesterone Containing Oral Dosage Forms and Related Methods
US20110312927A1 (en) * 2010-06-18 2011-12-22 Satish Kumar Nachaegari Progesterone Containing Oral Dosage Forms and Related Methods
US9301920B2 (en) * 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) * 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) * 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile

Also Published As

Publication number Publication date
EP3122364A1 (en) 2017-02-01
IL247828A0 (en) 2016-11-30
CA2942568A1 (en) 2015-10-01
MX2016011706A (en) 2017-05-01
EP3122364A4 (en) 2017-10-25
WO2015148952A1 (en) 2015-10-01
RU2016136666A (en) 2018-05-03
JP2017509630A (en) 2017-04-06
KR20160137597A (en) 2016-11-30
JP2019206540A (en) 2019-12-05
AU2015237243A1 (en) 2016-09-29
RU2016136666A3 (en) 2018-11-07

Similar Documents

Publication Publication Date Title
PH12017501097A1 (en) Sunitinib formulations and methods for use thereof in treatment of ocular disorders
BR112012033077B8 (en) PHARMACEUTICAL COMPOSITION FOR INTRAVENOUS ADMINISTRATION, USE OF A PHARMACEUTICAL COMPOSITION, AND, KIT
CL2019000248A1 (en) Modulators of the nmda spiro-lactam receptor and use thereof
CO2019000938A2 (en) Nmda spiro-lactam modulators and methods of use thereof
CL2016001874A1 (en) Solid oral modified release dosage form comprising pridopidine and a speed control excipient; pharmaceutical formulation comprising the dosage form; use of the dosage form or pharmaceutical formulation to treat a neurodegenerative or dopamine-related disease, such as huntington's disease, among others.
CO2019000943A2 (en) Modulators of the nmda spiro-lactam receptor and use thereof
CR20140086A (en) COMBINATION TREATMENTS FOR HEPATITIS C
AR084816A1 (en) METHODS AND MEDICINES FOR THE TREATMENT OF ALZHEIMER'S DISEASE
CL2019002190A1 (en) Reduction of the viscosity of pharmaceutical formulations that comprise a therapeutic protein at a concentration of at least 70 mg / ml, where the therapeutic protein is not an antibody (divisional application 201700984)
AR085662A1 (en) METHODS AND COMPOSITIONS TO TREAT HYPERURICEMIA AND METABOLIC DISORDERS ASSOCIATED WITH HYPERURICEMIA
AR096892A1 (en) A PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA
PE20181332A1 (en) METHODS OF SEDATION AND PARENTERAL FORMULATION FOR USE DURING THE TREATMENT OF CRITICAL CARE
CL2019003533A1 (en) Use of vibegron to treat overactive bladder.
DOP2016000254A (en) PHARMECEUTIC FORMULATIONS OF PAN-RAF QUINASE INHIBITOR, PROCEDURES FOR THEIR PREPARATION, AND METHODS OF USE.
CO2019004004A2 (en) Pharmaceutical composition and method for the treatment of non-alcoholic fatty liver disease
AR099872A1 (en) PROGESTERONE FORMULATIONS
CL2021002107A1 (en) Triamterene or nolatrexed for use in the treatment of phenylketonuria.
BR112012030654A2 (en) bendamustine oral dosage forms
CL2016002318A1 (en) Pharmaceutical composition in the form of a solution comprising a liquid carrier comprising water and between 20% and 95% of one or more alcohols and sildenafil citrate dissolved in said liquid carrier at a concentration of between 7 and 125 mg / ml; methods to obtain it; oral dosage form; oral dosage form; kits
CL2020000601A1 (en) Pharmaceutical composition.
AR099299A1 (en) INHIBITOR OF THE CHOLESTERILE ESTER TRANSFER PROTEIN (CETP) AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE SUCH INHIBITOR FOR USE IN THE TREATMENT OR PREVENTION OF CARDIOVASCULAR DISEASES
AR086491A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING FEXOFENADINE
CL2021000627A1 (en) Pharmaceutical compositions suitable for joint release and their use in the treatment of joint pain
BR112018008835A8 (en) oral pharmaceutical composition, oral pulsatile release pharmaceutical composition, method for treating a disease condition requiring dimethyl fumarate therapy and method for treating multiple sclerosis
CL2014003326A1 (en) Injectable antioxidant formulation for intravenous use of sodium ascorbate - in high doses, and n-acetylcysteine as oxidizing agents, and deferoxamine as iron chelating agents, plus pharmaceutical excipients; method for administration and use in preventing repertfusion damage in patients with acute myocardial infection, undergoing primary cardiac angioplasty; and kit that contains it.

Legal Events

Date Code Title Description
FB Suspension of granting procedure